Eli Lilly v Actavis. Mark Engelman Head of Intellectual Property

Similar documents
Dawn of an English Doctrine of Equivalents: immaterial variants infringe

Alchemy in the UK: the Supreme Court in Eli Lilly V Actavis transmutes sodium into potassium but will it provide gold for patentees?

EUROPEAN PATENT LITIGATORS ASSOCIATION (EPLIT)

Actavis in the Antipodes a doctrine of equivalents for New Zealand?

Patents Act 1977, Secs. 125 (1), (3) and 130 (7); European Patent Convention, Art "Epilady United Kingdom"

ACTAVIS UK LTD v ELI LILLY & CO

Keywords: patent, construction, infringement, Amgen, equivalents, protocol

ACTAVIS V ELI LILLY SHOULD WE HAVE SEEN IT COMING?

Patents Act 1977, Secs. 3, 60, 125 ; European Patent Convention, Protocol on the Interpretation of Art "Kastner"

Actavis v Eli Lilly - Are we clear now?

Lee Tat Cheng v Maka GPS Technologies Pte Ltd

Doctrine of Equivalents: Recent Developments in Germany

Doctrine of Equivalents: Recent Developments in Switzerland

Reversal decision of 15/10/2018 Case No /2017

Inside IP. Intelligent patents for artificial intelligence. European Intellectual Property Attorneys PAGE 11

RETAINING THE CATNIC/IMPROVER APPROACH IN PATENT LAW

OPINIONS OF THE LORDS OF APPEAL

THE DOCTRINE OF EQUIVALENTS IN VARIOUS PATENT REGIMES-DOES ANYBODY HAVE IT RIGHT?

PATENT. Vexed pemetrexed UK Supreme Court rewrites the law on scope of patent protection. no.60. Full Story Page 02. August 2017 In this issue:

A Road to Unification: Patent Litigation in the United Kingdom

Construction of second medical use claims. The Hon. Mr Justice Richard Arnold

Patentable Subject Matter and Medical Use Claims in the Pharmaceutical Sector

HOW HIGH HAS THE BAR BEEN RAISED? THE AUSTRALIAN PATENT OFFICE ISSUES ITS FIRST OPPOSITION DECISION ON A POST RAISING THE BAR PATENT APPLICATION

Attention: Ms Chung Ka Yee 29 January Re: Feedback on Proposed Changes to Chapter 8 Of The Examination Guidelines For Patent Applications

The Unitary Patent Plan Beta Update on National Case Law in Europe

The Community Patent System Proposal and Patent Infringement Proceedings: An Eye towards Greater Harmonization in European Intellectual Property Law

F2050-C I TER ATIO AL COURT OF ARBITRATIO, EW DELHI. GOOD HEALTH COMPA Y I TELLECTUAL PROPERTY DEPARTME T OF MARU MEMORIAL FOR THE CLAIMA T

Current Patent Litigation Trends: UK and Germany

IN THE INTERNATIONAL COURT OF ARBITRATION GOOD HEALTH COMPANY DIRECTOR OF IP, STATE OF MARU SUBMISSIONS OF COUNSEL FOR THE CLAIMANT

Second medical use or indication claims. Winnie Tham, Edmund Kok, Nicholas Ong

An introduction to European intellectual property rights

THE SUPREME COURT OF APPEAL OF SOUTH AFRICA JUDGMENT ORICA MINING SERVICES SA (PTY) LTD ELBROC MINING PRODUCTS (PTY) LTD

PATENT CLAIM INTERPRETATION What is the Game in North America? (An Outline) By J. Alan Aucoin

Chapter 2 Amendment Adding New Matter (Patent Act Article 17bis(3))

Where are we now with plausibility?

Second medical use or indication claims. Mr. Antonio Ray ORTIGUERA Angara Abello Concepcion Regala & Cruz Law Offices Philippines

FUNCTIONAL CLAIMING UNDER THE EPC General principles and case-law

Section I New Matter. (June 2010) 1. Relevant Provision

Bangkok, August 22 to 26, 2016 (face-to-face session) August 29 to October 30, 2016 (follow-up session)

"And then there were. 18 th Annual Patent Seminar. Gordon Harris, Legal01# v1[GDH]

International Court of Arbitration at New Delhi, India THE CASE OF COMPULSORY LICENSE AND PATENT INFRINGEMENT UNDER TRIPS GOOD HEALTH COMPANY

Intellectual Property Department Hong Kong, China. Contents

INTERNATIONAL COURT OF ARBITRATION NEW DELHI, INDIA GOOD HEALTH COMPANY CLAIMANT DIRECTOR OF INTELLECTUAL PROPERTY, STATE OF MARU RESPONDENT

Second medical use or indication claims. [Please insert name last name in CAPITAL letters please]

The Patent Examination Manual. Section 10: Meaning of useful. Meaning of useful. No clear statement of utility. Specific utility

Switzerland. Esther Baumgartner Christoph Berchtold Simon Holzer Kilian Schärli Meyerlustenberger Lachenal. 1. Small molecules

English Language Translation Entry into New Zealand PCT National Phase

Suzannah K. Sundby. canady + lortz LLP. David Read. Differences between US and EU Patent Laws that Could Cost You and Your Startup.

The use of prosecution history in post-grant patent proceedings. Maria CRUZ GARCIA, Isabel FRANCO, João JORGE, Teresa SILVA GARCIA

Actavis Group v. Eli Lilly: Cross-Border Infringement Jurisdiction

Claims and Determining Scope of Protection

Judgment of 20 October 2017 First Civil Law Chamber

Law on the protection of inventions No. 50/2008 of the Republic of Moldova can be found at:

AIPLA QUARTERLY JOURNAL

Infringement of Claims: The Doctrine of Equivalents and Related Issues German Position

The Patent Examination Manual. Section 7: Meaning of inventive step

Paper No Entered: September 30, 2016 UNITED STATES PATENT AND TRADEMARK OFFICE

APPENDIX 1 THE CURRENT AUSTRALIAN TESTS SUFFICIENCY

ti Litigating Patents Overseas: Country Specific Considerations Germany There is no "European" litigation system.

CHAPTER V PATENT SPECIFICATION AND CLAIMS

THE SAFE HARBOR PROVISION OF HATCH-WAXMAN IS THERE A HOLE IN THE SAFETY NET?

THE REPLACEMENT OF THE DOCTRINE OF PITH AND MARROW BY THE CATNIC TEST IN ENGLISH PATENT LAW: A HISTORICAL EVALUATION RAYMOND MNYAMEZELI MLUNGISI ZONDO

Application of Doctrine of Equivalents in Patent Infringement Disputes

The Myriad patent litigation Patentability of DNA molecules

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

Evidence in EPO Proceedings. Dr. Joachim Renken Madrid, November 14, 2016

Basic Patent Information from the USPTO (Redacted) November 15, 2007

Frequently Asked Questions. Trade/service marks: What is a trade/service mark?

Information and Guidelines Concerning the Patent and Copyright Process at East Tennessee State University

Plausibility, 2nd medical use and late amendments - The Dutch perspective after UK SC 14 Nov 2018 pregabalin case

United States Court of Appeals for the Federal Circuit

Harmonisation across Europe - comparison and interaction between the EPO appeal system and the national judicial systems

Update on the CRISPR IP Saga and lessons to be learnt. Claire Irvine and Cath Coombes #healthcare #intellectualproperty

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

Notwithstanding Article 29, any invention that is liable to injure public order, morality or public health shall not be patented (Article 32).

G3/08 PATENTABILITY OF SOFTWARE : DETAILS EXPECTED FROM

Chapter Patent Infringement --

Note: When any ambiguity of interpretation is found in this provisional translation, the Japanese text shall prevail.

The relationship between insufficiency and clarity Clear or unclear?

S A M P L E Q U E S T I O N S April 2002

It is all crystal clear by definition... (and don t blame us if it isn t)

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF INDIANA INDIANAPOLIS DIVISION ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights

Experimental Use Exemption of Patent Infringement A Brief Comparison of China and the United States

Lessons learnt 6 February 2015

The Same Invention or Not the Same Invention? Thorsten Bausch

Before : MR JUSTICE HENRY CARR Between : - and

Going full circle: Bolar in Europe and the UPC

[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights

ROMANIA Patent Law NO.64/1991 OFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014

Before: MR. JUSTICE HENRY CARR Between:

Patent Cooperation Treaty (PCT) Working Group

OFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014 REPUBLICATION PATENT LAW NO.64/1991 1

The Royal Society of Chemistry IP Law Case Seminar: 2017 in the U.S.

Second Medical Use Patents in Europe: Are the UK and Germany Swapping Approaches?

OLIVE & OLIVE, P.A. INTELLECTUAL PROPERTY LAW

Europe Divided Update on National Case Law in Europe

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

The use of prosecution history in post-grant patent proceedings

November Obvious To Try In Pharmaceutical Formulations. g Motivation To Combine. g Obviousness-Type Double Patenting

Transcription:

Eli Lilly v Actavis Mark Engelman Head of Intellectual Property mark.engelman@hardwicke.co.uk

Topics 1. Literalism 2. Ely Lilly v Actavis The Facts 3. Catnic Components Ltd v Hill & Smith Ltd [1982] RPC 183 4. Improver Corpn v Remington Consumer Products Ltd [1990] FSR 181 5. Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9 6. Ely Lilly v Activis The Law 7. Ely Lilly v Activis The Effects

1. Literalism Definition of LITERALISM adherence to the explicit substance of an idea or expression 'The question is,' said Alice, 'whether you can make words mean so many different things. Alice in Wonderland Lewis Carroll

2. Ely Lilly v Actavis The Facts Pemetrexed - an antitfolate in a disodium salt for carcinoma side effects ameliorated with vitamin B12

2. Ely Lilly v Actavis The Facts Actavis intended to launch its drug with (a) pemetrexed diacid, (b) pemetrexed ditromethamine, or (c) pemetrexed dipotassium but crucially not the disodium salt,

2. Ely Lilly v Actavis The Facts Eli Lilly argued the Actavis s product : (a) as an equivalent infringed its patent because it fell within the claims or (b) because the disodium salt is created in the course of manufacturing pemetrexed.

3. Catnic Components Ltd v Hill & Smith Ltd Distinction drawn between: textual infringement and infringement of the pith and marrow of the invention. "A patent specification should be given a purposive construction rather than a purely literal one understanding language in accordance with what a reasonable person would understand the author to be using the words to mean

3. Catnic Components Ltd v Hill & Smith Ltd

4. Improver Corpn v Remington Consumer Products Ltd

4. Improver Corpn v Remington Consumer Products Ltd Patent covered a depilatory device having a curved "helical spring" driven by a motor. The spring when rotated gripped hairs between its coils and plucked them from the skin. The alleged infringement replaced the spring with a rubber rod having slits in its surface. The question was whether the slitted rubber rod was "a helical spring".

4. Improver Corpn v Remington Consumer Products Ltd the Improver Questions : (1) Does a variant (to an element of a patent claim) have a material effect upon the way the invention works? If yes, the variant is outside the claim. If no (2) Would this (ie, that the variant had no material effect) have been obvious at the date of publication of the patent to a reader skilled in the art? If no, the variant is outside the claim. If yes (3) Would the reader skilled in the art nevertheless have understood from the language of the claim that the patentee intended that strict compliance with the primary meaning was an essential requirement of the invention? If yes, the variant is outside the claim.

4. Improver Corpn v Remington Consumer Products Ltd On the other hand, a negative answer to the last question would lead to the conclusion that the patentee was intending the word or phrase to have not a literal, but a figurative meaning (the figure being a form of synecdoche or metonymy) denoting a class of things which included the variant and the literal meaning, the latter being perhaps the most perfect, best-known or striking example of the class.

Held: (i) (ii) 4. Improver Corpn v Remington Consumer Products Ltd the change to a rubber rod had no material effect on the way the invention worked; and it would have been obvious to an expert that the rubber rod would work in the same way; (iii) but (iii) the expert would have understood from the patent that the patentee meant to confine his claim to a "helical spring", in its primary meaning and not in a wide generic sense. For this last reason, the rubber rod did not infringe.

Art.69(1) 4. Improver Corpn v Remington Consumer Products Ltd should not be interpreted as meaning that the extent of the protection is to be understood as that defined by the strict, literal meaning of the wording used in the claims, the description and drawings being employed only for the purpose of resolving an ambiguity found in the claims.

4. Improver Corpn v Remington Consumer Products Ltd Art.69(1) Nor should it be taken to mean that the claims serve only as a guideline and that the actual protection conferred may extend to what, from a consideration of the description and drawings by a person skilled in the art, the patent proprietor has contemplated. On the contrary, it is to be interpreted as defining a position between these extremes which combines a fair protection for the patent proprietor with a reasonable degree of legal certainty for third parties.

4. Improver Corpn v Remington Consumer Products Ltd Art.69(2) - Equivalents For the purpose of determining the extent of protection conferred by a European patent, due account shall be taken of any element which is equivalent to an element specified in the claims.

5. Kirin-Amgen Inc v Hoechst Marion Roussel Ltd Technologies employed by the two parties for producing the hormone erythropoietin

5. Kirin-Amgen Inc v Hoechst Marion Roussel Ltd C: a DNA sequence for use in securing the expression of EPO in a host cell versus D: TKT method did not involve using a "DNA sequence for use in securing expression (of EPO) in a host cell"

5. Kirin-Amgen Inc v Hoechst Marion Roussel Ltd D made EPO by an endogenous DNA sequence coding for EPO in a human cell into which an exogenous promoter sequence has been inserted

5. Kirin-Amgen Inc v Hoechst Marion Roussel Ltd to adopt a principle of construction which actually gave effect to what the person skilled in the art would have understood the patentee to be claiming.

5. Kirin-Amgen Inc v Hoechst Marion Roussel Ltd Interpreting the claims of the Amgen patent in the context of its specification, the claims were concerned with the expression of EPO by a gene which is exogenous to the cell. But the genes which express EPO in cells by the TKT process are not exogenous.

5. Kirin-Amgen Inc v Hoechst Marion Roussel Ltd The HL rejected literalism over a purposive construction (adopting Catnic): to adopt a principle of construction which actually gave effect to what the person skilled in the art would have understood the patentee to be claiming. (not what the author of the words thought them to mean cf Alice)

5. Kirin-Amgen Inc v Hoechst Marion Roussel Ltd Additionally, if a claim is intended to cover products or processes which involve the use of technology unknown at the time the claim was drafted, then the patent specification and claims based thereon should be drafted so that a person skilled in the art would understand the description in a way which was sufficiently general to include the new technology.

5. Kirin-Amgen Inc v Hoechst Marion Roussel Ltd But Kiren-Amgen was not really an equivalents type case.

6. Ely Lilly v Activis The Law Activis is: Does K2=Na2?

6. Ely Lilly v Activis The Law Claim 1: Use of pemetrexed disodium in the manufacture of a medicament for use in combination therapy for inhibiting tumor growth in mammals wherein said medicament is to be administered in combination with vitamin B12 or a pharmaceutical derivative thereof [which it then specifies].

6. Ely Lilly v Activis The Law The central contention between Eli Lilly and Actavis was whether the words pemetrexed disodium were to be read literally or purposively? If the latter, they include either a pemetrexed diacid or a pemetrexed salt with vitamin B12, which represents the essence of the patent.

Neuberger LJ: 6. Ely Lilly v Activis The Law (i) does the variant infringe any of the claims as a matter of normal interpretation; and, if not, (ii) does the variant nonetheless infringe because it varies from the invention in a way or ways which is or are immaterial? (iii) If the answer to either issue is yes, there is an infringement; otherwise, there is not.

6. Ely Lilly v Activis The Law What does immaterial mean? Would it be obvious to the person skilled in the art, reading the patent at the priority date, but knowing that the variant achieves substantially the same result as the invention, that it does so in substantially the same way as the invention?

6. Ely Lilly v Activis The Law Now applying the facts: Question 1: Does the variant infringe any of the claims as a matter of normal interpretation;

6. Ely Lilly v Activis The Law Now applying the facts: Answer 1: No

6. Ely Lilly v Activis The Law Now applying the facts: Question 2: Would it be obvious to the person skilled in the art, reading the patent at the priority date, but knowing that the variant achieves substantially the same result as the invention, that it does so in substantially the same way as the invention?

6. Ely Lilly v Activis The Law Now applying the facts: Answer 2: The chemical variants in Actavis' product: (a) pemetrexed diacid, (b) pemetrexed ditromethamine and (c) pemetrexed dipotassium were equivalents of the disodium salt. They did not have a material effect upon the way the invention works.

6. Ely Lilly v Activis The Law Now applying the facts: Answer 2, Rule 1: Lord Neuberger drew upon references in its specification to the words other anti-folate drugs which have a similar effect to pemetrexed disodium.

6. Ely Lilly v Activis The Law Now applying the facts: Answer 2, Rule 2: He refused to take into account any exchanges between the patent office and the patentee during the prosecution of the patent.

6. Ely Lilly v Activis The Law Now applying the facts: Question 3: If the answer to either issue is yes, there is an infringement; otherwise, there is not. Thus, there was an infringement.

7. Ely Lilly v Activis The Effects The doctrine of equivalents is alive and well The prosecution history is irrelevant The wording of the specification remains important Invalidity might be dealt with the same way is this patent claim invalid because the prior art has an equivalent